,date,title,url
0,2001-03-01,恒瑞医药年报,/disclosure/listedinfo/announcement/c/600276_2000_0.pdf
1,2001-06-01,恒瑞医药上市公司章程,/disclosure/listedinfo/announcement/c/600276_2001_g.pdf
2,2001-07-28,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/600276_2001_1.pdf
3,2001-09-07,恒瑞医药回访报告,/disclosure/listedinfo/announcement/c/600276_20010907_1.pdf
4,2002-01-29,恒瑞医药上市公司章程,/disclosure/listedinfo/announcement/c/600276_20020129_g.pdf
5,2002-03-12,恒瑞医药年报,/disclosure/listedinfo/announcement/c/600276_2001_n.pdf
6,2002-04-23,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/600276_2002_1.pdf
7,2002-06-21,恒瑞医药回访报告,/disclosure/listedinfo/announcement/c/600276_20020621_1.pdf
8,2002-06-25,恒瑞医药董事会战略委员会实施细则,/disclosure/listedinfo/announcement/c/600276_20020625_4.pdf
9,2002-06-25,恒瑞医药董事会薪酬与考核委员会实施细则,/disclosure/listedinfo/announcement/c/600276_20020625_1.pdf
10,2002-06-25,恒瑞医药董事会提名委员会实施细则,/disclosure/listedinfo/announcement/c/600276_20020625_3.pdf
11,2002-06-25,恒瑞医药董事会审计委员会实施细则,/disclosure/listedinfo/announcement/c/600276_20020625_2.pdf
12,2002-06-26,恒瑞医药股东大会决议公告,/disclosure/listedinfo/announcement/c/600276_20020626_2.pdf
13,2002-06-26,恒瑞医药股东大会会议资料,/disclosure/listedinfo/announcement/c/600276_20020626_1.pdf
14,2002-08-06,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/600276_2002_z.pdf
15,2002-10-25,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2002-10-25/600276_2002_3.pdf
16,2003-04-22,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2003-04-22/600276_2002_n.pdf
17,2003-04-22,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2003-04-22/600276_2003_1.pdf
18,2003-06-14,恒瑞医药股东大会会议资料,/disclosure/listedinfo/announcement/c/2003-06-14/600276_20030614_1.pdf
19,2003-08-18,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2003-08-18/600276_2003_z.pdf
20,2003-10-27,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2003-10-27/600276_2003_3.pdf
21,2003-12-02,恒瑞医药股东大会决议公告,/disclosure/listedinfo/announcement/c/2003-12-02/600276_20031202_2.pdf
22,2003-12-02,恒瑞医药股东大会会议资料,/disclosure/listedinfo/announcement/c/2003-12-02/600276_20031202_1.pdf
23,2003-12-03,恒瑞医药投资者关系管理制度,/disclosure/listedinfo/announcement/c/2003-12-03/600276_20031203_1.pdf
24,2004-02-18,恒瑞医药总经理工作细则,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_5.pdf
25,2004-02-18,恒瑞医药召开2003年度股东大会通知,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_3.pdf
26,2004-02-18,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2004-02-18/600276_2003_n.pdf
27,2004-02-18,恒瑞医药监事会议事规则,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_6.pdf
28,2004-02-18,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_2.pdf
29,2004-02-18,恒瑞医药董事会议事规则,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_4.pdf
30,2004-02-18,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_1.pdf
31,2004-02-18,恒瑞医药2003年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2004-02-18/600276_20040218_7.pdf
32,2004-03-13,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2004-03-13/600276_20040313_2.pdf
33,2004-03-13,恒瑞医药2003年度会计报表更正公告,/disclosure/listedinfo/announcement/c/2004-03-13/600276_20040313_1.pdf
34,2004-04-07,恒瑞医药2003年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2004-04-07/600276_20040407_1.pdf
35,2004-04-07,恒瑞医药2003年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2004-04-07/600276_20040407_3.pdf
36,2004-04-07,恒瑞医药2003年度股东大会法律意见书,/disclosure/listedinfo/announcement/c/2004-04-07/600276_20040407_2.pdf
37,2004-04-16,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2004-04-16/600276_2004_1.pdf
38,2004-05-12,恒瑞医药召开临时股东大会通知,/disclosure/listedinfo/announcement/c/2004-05-12/600276_20040512_5.pdf
39,2004-05-12,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2004-05-12/600276_20040512_4.pdf
40,2004-05-12,恒瑞医药独立董事意见,/disclosure/listedinfo/announcement/c/2004-05-12/600276_20040512_3.pdf
41,2004-05-12,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2004-05-12/600276_20040512_1.pdf
42,2004-05-12,恒瑞医药出售资产公告,/disclosure/listedinfo/announcement/c/2004-05-12/600276_20040512_2.pdf
43,2004-05-22,恒瑞医药2003年度分红派息实施公告,/disclosure/listedinfo/announcement/c/2004-05-22/600276_20040522_1.pdf
44,2004-06-16,恒瑞医药2004年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2004-06-16/600276_20040616_1.pdf
45,2004-06-16,恒瑞医药2004年第一次临时股东大会法律意见书,/disclosure/listedinfo/announcement/c/2004-06-16/600276_20040616_2.pdf
46,2004-08-10,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2004-08-10/600276_20040810_1.pdf
47,2004-08-10,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2004-08-10/600276_2004_zzy.pdf
48,2004-08-10,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2004-08-10/600276_2004_z.pdf
49,2004-10-23,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2004-10-23/600276_2004_3.pdf
50,2005-01-25,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2005-01-25/600276_2004_nzy.pdf
51,2005-01-25,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2005-01-25/600276_2004_n.pdf
52,2005-01-25,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2005-01-25/600276_20050125_2.pdf
53,2005-01-25,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2005-01-25/600276_20050125_1.pdf
54,2005-03-01,恒瑞医药2004年年度股东大会法律意见书,/disclosure/listedinfo/announcement/c/2005-03-01/600276_20050301_2.pdf
55,2005-03-01,恒瑞医药2004年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2005-03-01/600276_20050301_1.pdf
56,2005-03-01,恒瑞医药2004年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2005-03-01/600276_20050301_3.pdf
57,2005-04-23,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2005-04-23/600276_2005_1.pdf
58,2005-06-10,恒瑞医药2004年度分红派息实施公告,/disclosure/listedinfo/announcement/c/2005-06-10/600276_20050610_1.pdf
59,2005-06-15,恒瑞医药2004年度分红派息补充公告,/disclosure/listedinfo/announcement/c/2005-06-15/600276_20050615_1.pdf
60,2005-07-21,恒瑞医药股权转让公告,/disclosure/listedinfo/announcement/c/2005-07-21/600276_20050721_1.pdf
61,2005-07-21,恒瑞医药股东增持持股变动报告书,/disclosure/listedinfo/announcement/c/2005-07-21/600276_20050721_2.pdf
62,2005-07-21,恒瑞医药股东减持持股变动报告书,/disclosure/listedinfo/announcement/c/2005-07-21/600276_20050721_3.pdf
63,2005-08-09,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2005-08-09/600276_2005_zzy.pdf
64,2005-08-09,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2005-08-09/600276_2005_z.pdf
65,2005-10-20,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2005-10-20/600276_2005_3.pdf
66,2005-12-28,恒瑞医药股东变更的公告,/disclosure/listedinfo/announcement/c/2005-12-28/600276_20051228_1.pdf
67,2005-12-29,恒瑞医药股东增持持股变动报告书,/disclosure/listedinfo/announcement/c/2005-12-29/600276_20051229_1.pdf
68,2006-02-14,恒瑞医药投资成立HENGRUI （USA） LTD 的公告,/disclosure/listedinfo/announcement/c/2006-02-14/600276_20060214_1.pdf
69,2006-02-24,恒瑞医药收购报告书（摘要）,/disclosure/listedinfo/announcement/c/2006-02-24/600276_20060224_1.pdf
70,2006-02-24,恒瑞医药国有股权转让的提示公告,/disclosure/listedinfo/announcement/c/2006-02-24/600276_20060224_3.pdf
71,2006-02-24,恒瑞医药股东减持持股变动报告书,/disclosure/listedinfo/announcement/c/2006-02-24/600276_20060224_2.pdf
72,2006-03-29,恒瑞医药与关联方资金往来的专项说明,/disclosure/listedinfo/announcement/c/2006-03-29/600276_20060329_3.pdf
73,2006-03-29,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2006-03-29/600276_2005_nzy.pdf
74,2006-03-29,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2006-03-29/600276_2005_n.pdf
75,2006-03-29,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2006-03-29/600276_20060329_2.pdf
76,2006-03-29,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2006-03-29/600276_20060329_1.pdf
77,2006-04-19,恒瑞医药关于2005年年度股东大会临时提案的公告,/disclosure/listedinfo/announcement/c/2006-04-19/600276_20060419_1.pdf
78,2006-04-21,恒瑞医药关于解除公司国有股权转让协议的公告,/disclosure/listedinfo/announcement/c/2006-04-21/600276_20060421_1.pdf
79,2006-04-21,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2006-04-21/600276_2006_1.pdf
80,2006-04-29,恒瑞医药2005年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2006-04-29/600276_20060429_2.pdf
81,2006-04-29,恒瑞医药2005年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2006-04-29/600276_20060429_1.pdf
82,2006-05-08,恒瑞医药关于召开公司股权分置改革相关股东会议的通知,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_1.pdf
83,2006-05-08,恒瑞医药股权分置改革之保荐意见书,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_4.pdf
84,2006-05-08,恒瑞医药股权分置改革说明书（摘要）,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_3.pdf
85,2006-05-08,恒瑞医药股权分置改革说明书,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_2.pdf
86,2006-05-08,恒瑞医药股权分置改革的法律意见书,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_5.pdf
87,2006-05-08,恒瑞医药独立董事关于股权分置改革之独立意见,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_6.pdf
88,2006-05-08,恒瑞医药董事会投票委托征集函,/disclosure/listedinfo/announcement/c/2006-05-08/600276_20060508_7.pdf
89,2006-05-11,恒瑞医药关于举办股权分置改革网上交流会的公告,/disclosure/listedinfo/announcement/c/2006-05-11/600276_20060511_1.pdf
90,2006-05-17,恒瑞医药关于股权分置改革方案沟通协商情况暨调整股权分置改革方案的公告,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_1.pdf
91,2006-05-17,恒瑞医药股权分置改革之补充保荐意见书,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_4.pdf
92,2006-05-17,恒瑞医药股权分置改革说明书摘要（修订稿）,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_3.pdf
93,2006-05-17,恒瑞医药股权分置改革说明书（修订稿）,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_2.pdf
94,2006-05-17,恒瑞医药股权分置改革的补充法律意见书,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_5.pdf
95,2006-05-17,恒瑞医药独立董事关于股权分置改革修订方案之独立意见,/disclosure/listedinfo/announcement/c/2006-05-17/600276_20060517_6.pdf
96,2006-05-23,恒瑞医药关于股票异常波动的公告,/disclosure/listedinfo/announcement/c/2006-05-23/600276_20060523_1.pdf
97,2006-05-24,恒瑞医药关于召开相关股东会议的第一次提示性公告,/disclosure/listedinfo/announcement/c/2006-05-24/600276_20060524_1.pdf
98,2006-05-29,恒瑞医药关于召开相关股东会议的第二次提示性公告,/disclosure/listedinfo/announcement/c/2006-05-29/600276_20060529_1.pdf
99,2006-06-05,恒瑞医药股权分置改革相关股东会议的法律意见书,/disclosure/listedinfo/announcement/c/2006-06-05/600276_20060605_2.pdf
100,2006-06-05,恒瑞医药股权分置改革相关股东会议表决结果公告,/disclosure/listedinfo/announcement/c/2006-06-05/600276_20060605_1.pdf
101,2006-06-15,恒瑞医药股权分置改革方案实施公告,/disclosure/listedinfo/announcement/c/2006-06-15/600276_20060615_1.pdf
102,2006-07-01,G恒瑞实际控制人变化公告,/disclosure/listedinfo/announcement/c/2006-07-01/600276_20060701_1.pdf
103,2006-07-12,G恒瑞2005年度分红派息实施公告,/disclosure/listedinfo/announcement/c/2006-07-12/600276_20060712_1.pdf
104,2006-07-19,G恒瑞董事会决议公告,/disclosure/listedinfo/announcement/c/2006-07-19/600276_20060719_1.pdf
105,2006-07-19,G恒瑞半年报摘要,/disclosure/listedinfo/announcement/c/2006-07-19/600276_2006_zzy.pdf
106,2006-07-19,G恒瑞半年报,/disclosure/listedinfo/announcement/c/2006-07-19/600276_2006_z.pdf
107,2006-08-17,G恒瑞2006年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2006-08-17/600276_20060817_1.pdf
108,2006-08-17,G恒瑞2006年第一次临时股东大会会议资料,/disclosure/listedinfo/announcement/c/2006-08-17/600276_20060817_3.pdf
109,2006-08-17,G恒瑞2006年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2006-08-17/600276_20060817_2.pdf
110,2006-08-23,G恒瑞转增股本实施公告,/disclosure/listedinfo/announcement/c/2006-08-23/600276_20060823_1.pdf
111,2006-10-20,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2006-10-20/600276_2006_3.pdf
112,2006-11-09,恒瑞医药诉讼公告,/disclosure/listedinfo/announcement/c/2006-11-09/600276_20061109_1.pdf
113,2007-01-11,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2007-01-11/600276_20070111_2.pdf
114,2007-01-11,恒瑞医药关于召开2007年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2007-01-11/600276_20070111_5.pdf
115,2007-01-11,恒瑞医药独立董事提名人声明,/disclosure/listedinfo/announcement/c/2007-01-11/600276_20070111_3.pdf
116,2007-01-11,恒瑞医药独立董事候选人声明,/disclosure/listedinfo/announcement/c/2007-01-11/600276_20070111_4.pdf
117,2007-01-11,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2007-01-11/600276_20070111_1.pdf
118,2007-01-18,恒瑞医药股票交易价格异常波动公告,/disclosure/listedinfo/announcement/c/2007-01-18/600276_20070118_1.pdf
119,2007-01-25,恒瑞医药简式权益变动报告书,/disclosure/listedinfo/announcement/c/2007-01-25/600276_20070125_2.pdf
120,2007-01-25,恒瑞医药股东变更的公告,/disclosure/listedinfo/announcement/c/2007-01-25/600276_20070125_1.pdf
121,2007-02-06,恒瑞医药2007年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2007-02-06/600276_20070206_1.pdf
122,2007-02-06,恒瑞医药2007年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2007-02-06/600276_20070206_2.pdf
123,2007-02-08,恒瑞医药与关联方资金往来的专项说明,/disclosure/listedinfo/announcement/c/2007-02-08/600276_20070208_4.pdf
124,2007-02-08,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2007-02-08/600276_2006_nzy.pdf
125,2007-02-08,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2007-02-08/600276_2006_n.pdf
126,2007-02-08,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2007-02-08/600276_20070208_3.pdf
127,2007-02-08,恒瑞医药关于召开2006年度股东大会的通知,/disclosure/listedinfo/announcement/c/2007-02-08/600276_20070208_2.pdf
128,2007-02-08,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2007-02-08/600276_20070208_1.pdf
129,2007-03-07,恒瑞医药2007年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2007-03-07/600276_20070307_2.pdf
130,2007-03-07,恒瑞医药2006年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2007-03-07/600276_20070307_1.pdf
131,2007-03-27,恒瑞医药2006年度分红派息实施公告,/disclosure/listedinfo/announcement/c/2007-03-27/600276_20070327_1.pdf
132,2007-04-10,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2007-04-10/600276_20070410_1.pdf
133,2007-04-10,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2007-04-10/600276_2007_1.pdf
134,2007-06-13,恒瑞医药诉讼公告,/disclosure/listedinfo/announcement/c/2007-06-13/600276_20070613_1.pdf
135,2007-06-15,恒瑞医药有限售条件的流通股上市公告,/disclosure/listedinfo/announcement/c/2007-06-15/600276_20070615_1.pdf
136,2007-06-28,恒瑞医药信息披露事务管理制度,/disclosure/listedinfo/announcement/c/2007-06-28/600276_20070628_2.pdf
137,2007-06-28,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2007-06-28/600276_20070628_1.pdf
138,2007-06-30,恒瑞医药关于“加强上市公司治理专项活动”自查情况报告,/disclosure/listedinfo/announcement/c/2007-06-30/600276_20070630_2.pdf
139,2007-06-30,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2007-06-30/600276_20070630_1.pdf
140,2007-08-08,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2007-08-08/600276_2007_zzy.pdf
141,2007-08-08,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2007-08-08/600276_2007_z.pdf
142,2007-09-18,恒瑞医药诉讼公告,/disclosure/listedinfo/announcement/c/2007-09-18/600276_20070918_1.pdf
143,2007-10-09,恒瑞医药2007年1-9月份业绩预增公告,/disclosure/listedinfo/announcement/c/2007-10-09/600276_20071009_1.pdf
144,2007-10-23,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2007-10-23/600276_2007_3.pdf
145,2007-11-02,恒瑞医药关于股东减持公司股票情况的公告,/disclosure/listedinfo/announcement/c/2007-11-02/600276_20071102_1.pdf
146,2008-01-08,恒瑞医药2007年年度业绩预增公告,/disclosure/listedinfo/announcement/c/2008-01-08/600276_20080108_1.pdf
147,2008-02-28,恒瑞医药与关联方非经营性资金往来及对外违规担保等情况的专项说明,/disclosure/listedinfo/announcement/c/2008-02-28/600276_20080228_4.pdf
148,2008-02-28,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2008-02-28/600276_2007_nzy.pdf
149,2008-02-28,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2008-02-28/600276_2007_n.pdf
150,2008-02-28,恒瑞医药监事会决议公告,/disclosure/listedinfo/announcement/c/2008-02-28/600276_20080228_3.pdf
151,2008-02-28,恒瑞医药关于召开2007年度股东大会的通知,/disclosure/listedinfo/announcement/c/2008-02-28/600276_20080228_2.pdf
152,2008-02-28,恒瑞医药独立董事年报工作制度,/disclosure/listedinfo/announcement/c/2008-02-28/600276_20080228_5.pdf
153,2008-02-28,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2008-02-28/600276_20080228_1.pdf
154,2008-03-22,恒瑞医药2007年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2008-03-22/600276_20080322_1.pdf
155,2008-03-27,恒瑞医药2007年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2008-03-27/600276_20080327_1.pdf
156,2008-03-27,恒瑞医药2007年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2008-03-27/600276_20080327_2.pdf
157,2008-04-07,恒瑞医药2007年度分红派息实施公告,/disclosure/listedinfo/announcement/c/2008-04-07/600276_20080407_1.pdf
158,2008-04-25,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2008-04-25/600276_2008_1.pdf
159,2008-05-07,恒瑞医药诉讼进展公告,/disclosure/listedinfo/announcement/c/2008-05-07/600276_20080507_1.pdf
160,2008-06-14,恒瑞医药关于收购连云港华晨医药有限公司股权的公告,/disclosure/listedinfo/announcement/c/2008-06-14/600276_20080614_2.pdf
161,2008-06-14,恒瑞医药董事会决议公告,/disclosure/listedinfo/announcement/c/2008-06-14/600276_20080614_1.pdf
162,2008-06-14,恒瑞医药变更股改保荐机构的公告,/disclosure/listedinfo/announcement/c/2008-06-14/600276_20080614_3.pdf
163,2008-06-18,恒瑞医药有限售条件的流通股上市公告,/disclosure/listedinfo/announcement/c/2008-06-18/600276_20080618_2.pdf
164,2008-06-18,恒瑞医药变更股改保荐人的公告,/disclosure/listedinfo/announcement/c/2008-06-18/600276_20080618_1.pdf
165,2008-07-31,恒瑞医药关于公司治理整改情况的说明,/disclosure/listedinfo/announcement/c/2008-07-31/600276_20080731_2.pdf
166,2008-07-31,恒瑞医药第四届董事会第十一次会议决议公告,/disclosure/listedinfo/announcement/c/2008-07-31/600276_20080731_1.pdf
167,2008-08-01,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2008-08-01/600276_2008_zzy.pdf
168,2008-08-01,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2008-08-01/600276_2008_z.pdf
169,2008-10-25,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2008-10-25/600276_2008_3.pdf
170,2008-12-05,恒瑞医药敏感信息排查制度,/disclosure/listedinfo/announcement/c/2008-12-05/600276_20081205_2.pdf
171,2008-12-05,恒瑞医药第四届董事会第十五次会议决议公告,/disclosure/listedinfo/announcement/c/2008-12-05/600276_20081205_1.pdf
172,2008-12-23,恒瑞医药关于被认定为2008年第二批高新技术企业的公告,/disclosure/listedinfo/announcement/c/2008-12-23/600276_20081223_1.pdf
173,2009-02-18,恒瑞医药章程修正案,/disclosure/listedinfo/announcement/c/2009-02-18/600276_20090218_2.pdf
174,2009-02-18,恒瑞医药与关联方资金往来的专项说明,/disclosure/listedinfo/announcement/c/2009-02-18/600276_20090218_5.pdf
175,2009-02-18,恒瑞医药四届七次监事会决议公告,/disclosure/listedinfo/announcement/c/2009-02-18/600276_20090218_4.pdf
176,2009-02-18,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2009-02-18/600276_2008_nzy.pdf
177,2009-02-18,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2009-02-18/600276_2008_n.pdf
178,2009-02-18,恒瑞医药关于召开2008年度股东大会的通知,/disclosure/listedinfo/announcement/c/2009-02-18/600276_20090218_3.pdf
179,2009-02-18,恒瑞医药第四届董事会第十六次会议决议公告,/disclosure/listedinfo/announcement/c/2009-02-18/600276_20090218_1.pdf
180,2009-03-27,恒瑞医药2008年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2009-03-27/600276_20090327_1.pdf
181,2009-03-31,恒瑞医药2008年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2009-03-31/600276_20090331_1.pdf
182,2009-03-31,恒瑞医药2008年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2009-03-31/600276_20090331_2.pdf
183,2009-04-21,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2009-04-21/600276_2009_1.pdf
184,2009-04-24,恒瑞医药2008年利润分配实施公告,/disclosure/listedinfo/announcement/c/2009-04-24/600276_20090424_1.pdf
185,2009-04-29,恒瑞医药2008年利润分配实施更正公告,/disclosure/listedinfo/announcement/c/2009-04-29/600276_20090429_1.pdf
186,2009-06-17,恒瑞医药有限售条件的流通股上市公告,/disclosure/listedinfo/announcement/c/2009-06-17/600276_20090617_1.pdf
187,2009-08-05,恒瑞医药公告,/disclosure/listedinfo/announcement/c/2009-08-05/600276_20090805_1.pdf
188,2009-08-13,恒瑞医药股东减持公告,/disclosure/listedinfo/announcement/c/2009-08-13/600276_20090813_1.pdf
189,2009-08-20,恒瑞医药自主研发的创新药在美国开始临床试验的公告,/disclosure/listedinfo/announcement/c/2009-08-20/600276_20090820_1.pdf
190,2009-08-26,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2009-08-26/600276_2009_zzy.pdf
191,2009-08-26,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2009-08-26/600276_2009_z.pdf
192,2009-10-23,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2009-10-23/600276_2009_3.pdf
193,2010-01-27,恒瑞医药2009年年度业绩预增公告,/disclosure/listedinfo/announcement/c/2010-01-27/600276_20100127_1.pdf
194,2010-02-08,恒瑞医药与关联方资金往来的专项说明,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_4.pdf
195,2010-02-08,恒瑞医药四届十一次监事会决议公告,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_3.pdf
196,2010-02-08,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2010-02-08/600276_2009_nzy.pdf
197,2010-02-08,恒瑞医药年报信息披露重大差错责任追究制度,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_6.pdf
198,2010-02-08,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2010-02-08/600276_2009_n.pdf
199,2010-02-08,恒瑞医药内幕信息及知情人管理备案制度,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_5.pdf
200,2010-02-08,恒瑞医药关于召开2009年度股东大会的通知,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_2.pdf
201,2010-02-08,恒瑞医药第四届董事会第二十次会议决议公告,/disclosure/listedinfo/announcement/c/2010-02-08/600276_20100208_1.pdf
202,2010-02-26,恒瑞医药2009年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2010-02-26/600276_20100226_1.pdf
203,2010-03-02,恒瑞医药2009年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2010-03-02/600276_20100302_1.pdf
204,2010-03-02,恒瑞医药2009年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2010-03-02/600276_20100302_2.pdf
205,2010-03-10,恒瑞医药2009年利润分配实施公告,/disclosure/listedinfo/announcement/c/2010-03-10/600276_20100310_1.pdf
206,2010-03-27,恒瑞医药四届十二次监事会决议公告,/disclosure/listedinfo/announcement/c/2010-03-27/600276_20100327_2.pdf
207,2010-03-27,恒瑞医药关于召开2010年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2010-03-27/600276_20100327_3.pdf
208,2010-03-27,恒瑞医药第四届董事会第二十一次会议决议公告,/disclosure/listedinfo/announcement/c/2010-03-27/600276_20100327_1.pdf
209,2010-03-31,恒瑞医药关于成立连云港置业有限公司的公告,/disclosure/listedinfo/announcement/c/2010-03-31/600276_20100331_1.pdf
210,2010-04-03,恒瑞医药2010年第一次临时股东大会会议资料,/disclosure/listedinfo/announcement/c/2010-04-03/600276_20100403_1.pdf
211,2010-04-09,恒瑞医药停牌公告,/disclosure/listedinfo/announcement/c/2010-04-09/600276_20100409_1.pdf
212,2010-04-13,恒瑞医药限制性股票激励计划实施考核办法,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_9.pdf
213,2010-04-13,恒瑞医药高级管理人员提名即聘任程序的独立董事意见,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_3.pdf
214,2010-04-13,恒瑞医药独立董事关于公司A股限制性股票激励计划（草案）的独立意见,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_5.pdf
215,2010-04-13,恒瑞医药第五届监事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_6.pdf
216,2010-04-13,恒瑞医药第五届董事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_2.pdf
217,2010-04-13,恒瑞医药A股限制性股票激励计划（摘要）,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_4.pdf
218,2010-04-13,恒瑞医药A股限制性股票激励计划（草案）,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_7.pdf
219,2010-04-13,恒瑞医药2010年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_1.pdf
220,2010-04-13,恒瑞医药2010年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2010-04-13/600276_20100413_8.pdf
221,2010-04-20,恒瑞医药捐赠公告,/disclosure/listedinfo/announcement/c/2010-04-20/600276_20100420_1.pdf
222,2010-04-22,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2010-04-22/600276_2010_1.pdf
223,2010-06-09,恒瑞医药股权激励进展公告,/disclosure/listedinfo/announcement/c/2010-06-09/600276_20100609_1.pdf
224,2010-06-10,恒瑞医药关于召开2010年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_4.pdf
225,2010-06-10,恒瑞医药独立董事公开征集委托投票权报告书,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_3.pdf
226,2010-06-10,恒瑞医药第五届监事会第三次会议决议公告,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_5.pdf
227,2010-06-10,恒瑞医药第五届董事会第三次会议决议公告,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_1.pdf
228,2010-06-10,恒瑞医药A股限制性股票激励计划（修订稿摘要）,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_2.pdf
229,2010-06-10,恒瑞医药A股限制性股票激励计划（草案修订稿）,/disclosure/listedinfo/announcement/c/2010-06-10/600276_20100610_6.pdf
230,2010-06-17,恒瑞医药关于召开2010年第一次临时股东大会通知的提示性公告,/disclosure/listedinfo/announcement/c/2010-06-17/600276_20100617_1.pdf
231,2010-06-19,恒瑞医药更正公告,/disclosure/listedinfo/announcement/c/2010-06-19/600276_20100619_1.pdf
232,2010-06-22,恒瑞医药2010年第二次临时股东大会会议资料,/disclosure/listedinfo/announcement/c/2010-06-22/600276_20100622_1.pdf
233,2010-06-29,恒瑞医药2010年第二次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2010-06-29/600276_20100629_1.pdf
234,2010-06-29,恒瑞医药2010年第二次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2010-06-29/600276_20100629_2.pdf
235,2010-06-30,恒瑞医药独立董事就公司限制性股票激励计划相关事项发表的意见,/disclosure/listedinfo/announcement/c/2010-06-30/600276_20100630_2.pdf
236,2010-06-30,恒瑞医药第五届董事会第四次会议决议公告,/disclosure/listedinfo/announcement/c/2010-06-30/600276_20100630_1.pdf
237,2010-07-23,恒瑞医药独立董事就部分激励对象放弃或减少认购A股限制性股票所发表的意见,/disclosure/listedinfo/announcement/c/2010-07-23/600276_20100723_3.pdf
238,2010-07-23,恒瑞医药第五届监事会第四次会议决议公告,/disclosure/listedinfo/announcement/c/2010-07-23/600276_20100723_2.pdf
239,2010-07-23,恒瑞医药第五届董事会第五次会议决议公告,/disclosure/listedinfo/announcement/c/2010-07-23/600276_20100723_1.pdf
240,2010-07-29,恒瑞医药限制性股票授予完成的公告,/disclosure/listedinfo/announcement/c/2010-07-29/600276_20100729_1.pdf
241,2010-08-04,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2010-08-04/600276_20100804_1.pdf
242,2010-08-06,恒瑞医药关于成立连云港置业有限公司的公告,/disclosure/listedinfo/announcement/c/2010-08-06/600276_20100806_1.pdf
243,2010-08-07,恒瑞医药副总经理提名及聘任程序的独立董事意见,/disclosure/listedinfo/announcement/c/2010-08-07/600276_20100807_2.pdf
244,2010-08-07,恒瑞医药董事、监事及高管人员持股及变动管理制度,/disclosure/listedinfo/announcement/c/2010-08-07/600276_20100807_3.pdf
245,2010-08-07,恒瑞医药第五届董事会第六次会议决议公告,/disclosure/listedinfo/announcement/c/2010-08-07/600276_20100807_1.pdf
246,2010-08-07,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2010-08-07/600276_2010_zzy.pdf
247,2010-08-07,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2010-08-07/600276_2010_z.pdf
248,2010-10-30,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2010-10-30/600276_2010_3.pdf
249,2010-11-17,恒瑞医药股票交易异常波动公告,/disclosure/listedinfo/announcement/c/2010-11-17/600276_20101117_1.pdf
250,2010-12-10,恒瑞医药第五届董事会第八次会议决议公告,/disclosure/listedinfo/announcement/c/2010-12-10/600276_20101210_1.pdf
251,2011-02-11,恒瑞医药关于达宁退市的公告,/disclosure/listedinfo/announcement/c/2011-02-11/600276_20110211_1.pdf
252,2011-03-02,恒瑞医药与关联方资金往来的专项说明,/disclosure/listedinfo/announcement/c/2011-03-02/600276_20110302_4.pdf
253,2011-03-02,恒瑞医药五届七次监事会决议公告,/disclosure/listedinfo/announcement/c/2011-03-02/600276_20110302_3.pdf
254,2011-03-02,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2011-03-02/600276_2010_nzy.pdf
255,2011-03-02,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2011-03-02/600276_2010_n.pdf
256,2011-03-02,恒瑞医药关于召开2010年度股东大会的通知,/disclosure/listedinfo/announcement/c/2011-03-02/600276_20110302_2.pdf
257,2011-03-02,恒瑞医药第五届董事会第九次会议决议公告,/disclosure/listedinfo/announcement/c/2011-03-02/600276_20110302_1.pdf
258,2011-03-12,恒瑞医药2010年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2011-03-12/600276_20110312_1.pdf
259,2011-03-26,恒瑞医药2010年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2011-03-26/600276_20110326_1.pdf
260,2011-03-26,恒瑞医药2010年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2011-03-26/600276_20110326_2.pdf
261,2011-04-19,恒瑞医药2010年度利润分配及公积金转增股本实施公告,/disclosure/listedinfo/announcement/c/2011-04-19/600276_20110419_1.pdf
262,2011-04-25,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2011-04-25/600276_2011_1.pdf
263,2011-06-15,恒瑞医药关于艾瑞昔布获得国家一类新药批件及证书的公告,/disclosure/listedinfo/announcement/c/2011-06-15/600276_20110615_2.pdf
264,2011-06-15,恒瑞医药第五届董事会第十一次会议决议公告,/disclosure/listedinfo/announcement/c/2011-06-15/600276_20110615_1.pdf
265,2011-07-06,恒瑞医药关于股权激励股票首次解锁的公告,/disclosure/listedinfo/announcement/c/2011-07-06/600276_20110706_1.pdf
266,2011-08-06,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2011-08-06/600276_2011_zzy.pdf
267,2011-08-06,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2011-08-06/600276_2011_z.pdf
268,2011-10-28,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2011-10-28/600276_2011_3.pdf
269,2011-11-02,恒瑞医药关于公司董事买卖公司股票的公告,/disclosure/listedinfo/announcement/c/2011-11-02/600276_20111102_1.pdf
270,2011-12-20,恒瑞医药关于伊立替康注射液通过美国FDA认证的公告,/disclosure/listedinfo/announcement/c/2011-12-20/600276_20111220_1.pdf
271,2012-02-11,恒瑞医药关于收购北京恒森创新医药科技有限公司的公告,/disclosure/listedinfo/announcement/c/2012-02-11/600276_20120211_1.pdf
272,2012-03-20,恒瑞医药五届十一次监事会决议公告,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_3.pdf
273,2012-03-20,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2012-03-20/600276_2011_nzy.pdf
274,2012-03-20,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2012-03-20/600276_2011_n.pdf
275,2012-03-20,恒瑞医药关于召开2011年度股东大会的议案,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_2.pdf
276,2012-03-20,恒瑞医药关于董事及独立董事辞职的公告,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_4.pdf
277,2012-03-20,恒瑞医药独立董事2011年述职报告,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_6.pdf
278,2012-03-20,恒瑞医药第五届董事会第十五次会议决议公告,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_1.pdf
279,2012-03-20,恒瑞医药2011年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2012-03-20/600276_20120320_5.pdf
280,2012-03-31,恒瑞医药五届十六次董事会决议公告,/disclosure/listedinfo/announcement/c/2012-03-31/600276_20120331_1.pdf
281,2012-03-31,恒瑞医药实施内部控制规范工作方案,/disclosure/listedinfo/announcement/c/2012-03-31/600276_20120331_2.pdf
282,2012-03-31,恒瑞医药2011年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2012-03-31/600276_20120331_3.pdf
283,2012-04-12,恒瑞医药五届十七次董事会决议公告,/disclosure/listedinfo/announcement/c/2012-04-12/600276_20120412_2.pdf
284,2012-04-12,恒瑞医药2011年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2012-04-12/600276_20120412_1.pdf
285,2012-04-12,恒瑞医药2011年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2012-04-12/600276_20120412_3.pdf
286,2012-04-27,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2012-04-27/600276_2012_1.pdf
287,2012-05-18,恒瑞医药关于独资设立成都新越医药有限公司的公告,/disclosure/listedinfo/announcement/c/2012-05-18/600276_20120518_1.pdf
288,2012-05-22,恒瑞医药2011年度利润分配实施公告,/disclosure/listedinfo/announcement/c/2012-05-22/600276_20120522_1.pdf
289,2012-07-02,恒瑞医药关于股权激励股票第二次解锁的公告,/disclosure/listedinfo/announcement/c/2012-07-02/600276_20120702_1.pdf
290,2012-08-10,恒瑞医药五届十三次监事会决议公告,/disclosure/listedinfo/announcement/c/2012-08-10/600276_20120810_4.pdf
291,2012-08-10,恒瑞医药关于召开2012年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2012-08-10/600276_20120810_3.pdf
292,2012-08-10,恒瑞医药关于董事辞职的公告,/disclosure/listedinfo/announcement/c/2012-08-10/600276_20120810_2.pdf
293,2012-08-10,恒瑞医药第五届董事会第二十一次会议决议公告,/disclosure/listedinfo/announcement/c/2012-08-10/600276_20120810_1.pdf
294,2012-08-10,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2012-08-10/600276_2012_zzy.pdf
295,2012-08-10,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2012-08-10/600276_2012_z.pdf
296,2012-08-18,恒瑞医药2012年第一次临时股东大会资料,/disclosure/listedinfo/announcement/c/2012-08-18/600276_20120818_1.pdf
297,2012-08-24,恒瑞医药注射用奥沙利铂获准在欧盟上市销售的公告,/disclosure/listedinfo/announcement/c/2012-08-24/600276_20120824_1.pdf
298,2012-08-30,恒瑞医药五届二十二次董事会决议公告,/disclosure/listedinfo/announcement/c/2012-08-30/600276_20120830_2.pdf
299,2012-08-30,恒瑞医药2012年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2012-08-30/600276_20120830_1.pdf
300,2012-08-30,恒瑞医药2012年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2012-08-30/600276_20120830_3.pdf
301,2012-10-27,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2012-10-27/600276_2012_3.pdf
302,2013-02-21,恒瑞医药关于2012年度利润分配预案征求投资者意见的公告,/disclosure/listedinfo/announcement/c/2013-02-20/600276_20130221_1.pdf
303,2013-03-16,恒瑞医药实施内部控制规范工作方案,/disclosure/listedinfo/announcement/c/2013-03-15/600276_20130316_2.pdf
304,2013-03-16,恒瑞医药关联交易管理办法,/disclosure/listedinfo/announcement/c/2013-03-15/600276_20130316_3.pdf
305,2013-03-16,恒瑞医药第五届董事会第二十四次会议决议公告,/disclosure/listedinfo/announcement/c/2013-03-15/600276_20130316_1.pdf
306,2013-04-02,恒瑞医药审计报告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_13.pdf
307,2013-04-02,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2013-04-01/600276_2012_nzy.pdf
308,2013-04-02,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2013-04-01/600276_2012_n.pdf
309,2013-04-02,恒瑞医药会计估计变更的说明,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_10.pdf
310,2013-04-02,恒瑞医药关于召开2012年度股东大会的通知,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_7.pdf
311,2013-04-02,恒瑞医药关于选举职工代表监事的公告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_5.pdf
312,2013-04-02,恒瑞医药关于成都盛迪医药有限公司增资暨关联交易的公告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_6.pdf
313,2013-04-02,恒瑞医药独立董事事前认可声明,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_16.pdf
314,2013-04-02,恒瑞医药独立董事关于预计2013年度日常关联交易的独立意见,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_14.pdf
315,2013-04-02,恒瑞医药独立董事关于成都盛迪医药有限公司增资暨关联交易的独立意见,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_17.pdf
316,2013-04-02,恒瑞医药董事会审计委员会书面审核意见,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_15.pdf
317,2013-04-02,恒瑞医药第五届监事会第十五次会议决议公告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_4.pdf
318,2013-04-02,恒瑞医药第五届董事会第二十五次会议决议公告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_3.pdf
319,2013-04-02,恒瑞医药2012年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_12.pdf
320,2013-04-02,恒瑞医药2012年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_9.pdf
321,2013-04-02,恒瑞医药2012年度独立董事述职报告,/disclosure/listedinfo/announcement/c/2013-04-01/600276_20130402_11.pdf
322,2013-04-09,恒瑞医药2012年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2013-04-08/600276_20130409_1.pdf
323,2013-04-10,恒瑞医药关于召开2012年度网上业绩说明会的通知,/disclosure/listedinfo/announcement/c/2013-04-09/600276_20130410_2.pdf
324,2013-04-10,恒瑞医药关于召开2012年度股东大会通知的更正公告,/disclosure/listedinfo/announcement/c/2013-04-09/600276_20130410_1.pdf
325,2013-04-25,恒瑞医药独立董事关于高级管理人员提名及聘任程序的独立意见,/disclosure/listedinfo/announcement/c/2013-04-24/600276_20130425_6.pdf
326,2013-04-25,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2013-04-24/600276_2013_1.pdf
327,2013-04-25,恒瑞医药第六届监事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2013-04-24/600276_20130425_4.pdf
328,2013-04-25,恒瑞医药第六届董事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2013-04-24/600276_20130425_3.pdf
329,2013-04-25,恒瑞医药2012年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2013-04-24/600276_20130425_5.pdf
330,2013-04-25,恒瑞医药2012年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2013-04-24/600276_20130425_2.pdf
331,2013-05-18,恒瑞医药关于来曲唑片通过美国FDA认证的公告,/disclosure/listedinfo/announcement/c/2013-05-17/600276_20130518_1.pdf
332,2013-06-03,恒瑞医药2012年度利润分配实施公告,/disclosure/listedinfo/announcement/c/2013-06-02/600276_20130603_1.pdf
333,2013-07-02,恒瑞医药监事会关于公司股权激励股票第三次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2013-07-01/600276_20130702_4.pdf
334,2013-07-02,恒瑞医药关于股权激励股票第三次解锁的公告,/disclosure/listedinfo/announcement/c/2013-07-01/600276_20130702_1.pdf
335,2013-07-02,恒瑞医药股权激励计划之限制性股票第三次解锁事宜的法律意见,/disclosure/listedinfo/announcement/c/2013-07-01/600276_20130702_3.pdf
336,2013-07-02,恒瑞医药独立董事关于股权激励股票符合第三次解锁条件的独立意见,/disclosure/listedinfo/announcement/c/2013-07-01/600276_20130702_2.pdf
337,2013-08-17,恒瑞医药独立董事关于高级管理人员提名及聘任程序的独立意见,/disclosure/listedinfo/announcement/c/2013-08-16/600276_20130817_4.pdf
338,2013-08-17,恒瑞医药第六届董事会第三次会议决议公告,/disclosure/listedinfo/announcement/c/2013-08-16/600276_20130817_2.pdf
339,2013-08-17,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2013-08-16/600276_2013_zzy.pdf
340,2013-08-17,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2013-08-16/600276_2013_z.pdf
341,2013-10-10,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2013-10-09/600276_20131010_1.pdf
342,2013-10-29,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2013-10-28/600276_2013_3.pdf
343,2014-02-15,恒瑞医药关于会计师事务所转制更名的公告,/disclosure/listedinfo/announcement/c/2014-02-14/600276_20140215_1.pdf
344,2014-03-04,恒瑞医药独立董事关于聘任公司常务副总经理的独立意见,/disclosure/listedinfo/announcement/c/2014-03-03/600276_20140304_2.pdf
345,2014-03-04,恒瑞医药第六届董事会第五次会议决议公告,/disclosure/listedinfo/announcement/c/2014-03-03/600276_20140304_1.pdf
346,2014-03-11,恒瑞医药关于2013年度利润分配预案征求投资者意见的公告,/disclosure/listedinfo/announcement/c/2014-03-10/600276_20140311_1.pdf
347,2014-04-09,恒瑞医药限制性股票激励计划实施考核管理办法,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_18.pdf
348,2014-04-09,恒瑞医药限制性股票激励计划（草案）摘要公告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_2.pdf
349,2014-04-09,恒瑞医药审计委员会履职情况汇总报告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_14.pdf
350,2014-04-09,恒瑞医药审计报告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_8.pdf
351,2014-04-09,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2014-04-08/600276_2013_nzy.pdf
352,2014-04-09,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2014-04-08/600276_2013_n.pdf
353,2014-04-09,恒瑞医药内部控制审计报告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_12.pdf
354,2014-04-09,恒瑞医药关于召开2013年度股东大会的通知,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_4.pdf
355,2014-04-09,恒瑞医药关于更换财务总监的公告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_6.pdf
356,2014-04-09,恒瑞医药独立董事关于第六届董事会第六次会议有关事项的独立意见,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_15.pdf
357,2014-04-09,恒瑞医药第六届监事会第四次会议决议公告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_5.pdf
358,2014-04-09,恒瑞医药第六届董事会第六次会议决议公告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_3.pdf
359,2014-04-09,恒瑞医药：关于江苏恒瑞医药股份有限公司2013年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_9.pdf
360,2014-04-09,恒瑞医药：北京市君泽君律师事务所关于《江苏恒瑞医药股份有限公司限制性股票激励计划（草案）》的法律意见,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_16.pdf
361,2014-04-09,恒瑞医药2013年度内部控制评价报告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_11.pdf
362,2014-04-09,恒瑞医药2013年度独立董事述职报告,/disclosure/listedinfo/announcement/c/2014-04-08/600276_20140409_10.pdf
363,2014-04-10,恒瑞医药限制性股票激励计划（草案）,/disclosure/listedinfo/announcement/c/2014-04-09/600276_20140410_1.pdf
364,2014-04-10,恒瑞医药关于召开2013年度网上业绩说明会的通知,/disclosure/listedinfo/announcement/c/2014-04-09/600276_20140410_2.pdf
365,2014-04-16,恒瑞医药2013年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2014-04-15/600276_20140416_1.pdf
366,2014-04-28,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2014-04-27/600276_2014_1.pdf
367,2014-05-01,恒瑞医药2013年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2014-04-30/600276_20140501_2.pdf
368,2014-05-01,恒瑞医药2013年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2014-04-30/600276_20140501_1.pdf
369,2014-05-06,恒瑞医药关于召开2014年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2014-05-05/600276_20140506_2.pdf
370,2014-05-06,恒瑞医药关于独立董事公开征集投票权的公告,/disclosure/listedinfo/announcement/c/2014-05-05/600276_20140506_1.pdf
371,2014-05-09,恒瑞医药2013年度利润分配实施公告,/disclosure/listedinfo/announcement/c/2014-05-08/600276_20140509_1.pdf
372,2014-05-10,恒瑞医药2014年第一次临时股东大会会议资料,/disclosure/listedinfo/announcement/c/2014-05-09/600276_20140510_1.pdf
373,2014-05-23,恒瑞医药独立董事关于公司限制性股票激励计划授予事项的独立意见,/disclosure/listedinfo/announcement/c/2014-05-22/600276_20140523_5.pdf
374,2014-05-23,恒瑞医药第六届董事会第八次会议决议公告,/disclosure/listedinfo/announcement/c/2014-05-22/600276_20140523_2.pdf
375,2014-05-23,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司限制性股票授予事项的法律意见,/disclosure/listedinfo/announcement/c/2014-05-22/600276_20140523_4.pdf
376,2014-05-23,恒瑞医药2014年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2014-05-22/600276_20140523_1.pdf
377,2014-05-23,恒瑞医药2014年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2014-05-22/600276_20140523_3.pdf
378,2014-05-24,恒瑞医药限制性股票激励计划激励对象名单,/disclosure/listedinfo/announcement/c/2014-05-23/600276_20140524_2.pdf
379,2014-05-24,恒瑞医药关于限制性股票激励计划授予事项的公告,/disclosure/listedinfo/announcement/c/2014-05-23/600276_20140524_1.pdf
380,2014-06-07,恒瑞医药关于阿帕替尼开发进展的公告,/disclosure/listedinfo/announcement/c/2014-06-06/600276_20140607_1.pdf
381,2014-06-24,恒瑞医药关于注射用奥沙利铂通过美国FDA认证的公告,/disclosure/listedinfo/announcement/c/2014-06-23/600276_20140624_1.pdf
382,2014-07-18,恒瑞医药股权激励计划限制性股票授予结果公告,/disclosure/listedinfo/announcement/c/2014-07-17/600276_20140718_1.pdf
383,2014-07-22,恒瑞医药重大信息内部报告制度,/disclosure/listedinfo/announcement/c/2014-07-21/600276_20140722_2.pdf
384,2014-07-22,恒瑞医药风险投资管理制度,/disclosure/listedinfo/announcement/c/2014-07-21/600276_20140722_3.pdf
385,2014-07-22,恒瑞医药第六届董事会第九次会议决议公告,/disclosure/listedinfo/announcement/c/2014-07-21/600276_20140722_1.pdf
386,2014-08-16,恒瑞医药关于为成都盛迪医药有限公司提供担保的公告,/disclosure/listedinfo/announcement/c/2014-08-15/600276_20140816_1.pdf
387,2014-08-16,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2014-08-15/600276_2014_zzy.pdf
388,2014-08-16,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2014-08-15/600276_2014_z.pdf
389,2014-08-27,恒瑞医药关于控股股东名称变更的公告,/disclosure/listedinfo/announcement/c/2014-08-26/600276_20140827_1.pdf
390,2014-10-28,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2014-10-27/600276_2014_3.pdf
391,2014-11-05,恒瑞医药关于阿帕替尼获得国家1.1类新药批件及证书的公告,/disclosure/listedinfo/announcement/c/2014-11-04/600276_20141105_1.pdf
392,2014-11-11,恒瑞医药关于注射用环磷酰胺在美国上市销售的公告,/disclosure/listedinfo/announcement/c/2014-11-10/600276_20141111_1.pdf
393,2014-11-12,恒瑞医药关于在德国设立全资子公司的公告,/disclosure/listedinfo/announcement/c/2014-11-11/600276_20141112_1.pdf
394,2014-12-09,恒瑞医药关于美国检方撤销对我公司曹国庆博士全部指控的公告,/disclosure/listedinfo/announcement/c/2014-12-08/600276_20141209_1.pdf
395,2014-12-17,恒瑞医药关于公司股东减持股份后持股比例低于5%的提示性公告,/disclosure/listedinfo/announcement/c/2014-12-16/600276_20141217_1.pdf
396,2014-12-24,恒瑞医药第六届董事会第十三次会议决议公告,/disclosure/listedinfo/announcement/c/2014-12-23/600276_20141224_1.pdf
397,2014-12-27,恒瑞医药限制性股票激励计划激励对象名单,/disclosure/listedinfo/announcement/c/2014-12-26/600276_20141227_4.pdf
398,2014-12-27,恒瑞医药关于部分限制性股票激励计划授予事项的公告,/disclosure/listedinfo/announcement/c/2014-12-26/600276_20141227_1.pdf
399,2014-12-27,恒瑞医药独立董事关于部分限制性股票激励计划授予事项的独立意见,/disclosure/listedinfo/announcement/c/2014-12-26/600276_20141227_2.pdf
400,2014-12-27,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司部分限制性股票授予的法律意见,/disclosure/listedinfo/announcement/c/2014-12-26/600276_20141227_3.pdf
401,2015-01-17,恒瑞医药验资报告,/disclosure/listedinfo/announcement/c/2015-01-16/600276_20150117_2.pdf
402,2015-01-17,恒瑞医药股权激励计划部分限制性股票授予结果公告,/disclosure/listedinfo/announcement/c/2015-01-16/600276_20150117_1.pdf
403,2015-03-14,恒瑞医药关于公司股东累计减持比例达到1%的公告,/disclosure/listedinfo/announcement/c/2015-03-13/600276_20150314_1.pdf
404,2015-03-31,恒瑞医药审计委员会履职情况汇总报告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_12.pdf
405,2015-03-31,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2015-03-30/600276_2014_nzy.pdf
406,2015-03-31,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2015-03-30/600276_2014_n.pdf
407,2015-03-31,恒瑞医药关于召开2014年年度股东大会的通知,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_3.pdf
408,2015-03-31,恒瑞医药关于独立董事辞职的公告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_2.pdf
409,2015-03-31,恒瑞医药独立董事关于第六届董事会第十四次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_13.pdf
410,2015-03-31,恒瑞医药第六届监事会第八次会议决议公告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_5.pdf
411,2015-03-31,恒瑞医药第六届董事会第十四次会议决议公告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_4.pdf
412,2015-03-31,恒瑞医药：关于公司2014年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_8.pdf
413,2015-03-31,恒瑞医药2014年度审计报告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_7.pdf
414,2015-03-31,恒瑞医药2014年度内部控制审计报告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_11.pdf
415,2015-03-31,恒瑞医药2014年度内部控制评价报告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_10.pdf
416,2015-03-31,恒瑞医药2014年度独立董事述职报告,/disclosure/listedinfo/announcement/c/2015-03-30/600276_20150331_9.pdf
417,2015-04-01,恒瑞医药独立董事提名人声明,/disclosure/listedinfo/announcement/c/2015-03-31/600276_20150401_3.pdf
418,2015-04-01,恒瑞医药独立董事候选人声明,/disclosure/listedinfo/announcement/c/2015-03-31/600276_20150401_2.pdf
419,2015-04-01,恒瑞医药第六届董事会第十四次会议决议补充公告,/disclosure/listedinfo/announcement/c/2015-03-31/600276_20150401_1.pdf
420,2015-04-02,恒瑞医药章程修正案,/disclosure/listedinfo/announcement/c/2015-04-01/600276_20150402_2.pdf
421,2015-04-02,恒瑞医药关于2014年年度股东大会更正补充公告,/disclosure/listedinfo/announcement/c/2015-04-01/600276_20150402_1.pdf
422,2015-04-02,恒瑞医药公司章程,/disclosure/listedinfo/announcement/c/2015-04-01/600276_20150402_3.pdf
423,2015-04-03,恒瑞医药关于召开2014年度网上业绩说明会的通知,/disclosure/listedinfo/announcement/c/2015-04-02/600276_20150403_3.pdf
424,2015-04-03,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2015-04-02/600276_20150403_1.pdf
425,2015-04-03,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2015-04-02/600276_20150403_2.pdf
426,2015-04-03,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2015-04-02/600276_20150403_4.pdf
427,2015-04-11,恒瑞医药2014年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2015-04-10/600276_20150411_1.pdf
428,2015-04-18,恒瑞医药第一季度季报,/disclosure/listedinfo/announcement/c/2015-04-17/600276_2015_1.pdf
429,2015-05-07,恒瑞医药第六届董事会第十六次会议决议公告,/disclosure/listedinfo/announcement/c/2015-05-06/600276_20150507_2.pdf
430,2015-05-07,恒瑞医药2014年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2015-05-06/600276_20150507_1.pdf
431,2015-05-07,恒瑞医药2014年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2015-05-06/600276_20150507_3.pdf
432,2015-05-27,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2015-05-26/600276_20150527_1.pdf
433,2015-06-09,恒瑞医药2014年度利润分配及资本公积转增股本实施公告,/disclosure/listedinfo/announcement/c/2015-06-08/600276_20150609_1.pdf
434,2015-07-14,恒瑞医药监事会关于部分股权激励股票第一次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_6.pdf
435,2015-07-14,恒瑞医药关于在苏州设立全资子公司的公告,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_3.pdf
436,2015-07-14,恒瑞医药关于部分股权激励股票第一次解锁的公告,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_1.pdf
437,2015-07-14,恒瑞医药独立董事关于第六届董事会第十七次会议有关事项的独立意见,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_5.pdf
438,2015-07-14,恒瑞医药第六届董事会第十七次会议决议公告,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_2.pdf
439,2015-07-14,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司限制性股票激励计划解锁事项的法律意见,/disclosure/listedinfo/announcement/c/2015-07-13/600276_20150714_4.pdf
440,2015-07-31,恒瑞医药关于引进美国Tesaro公司产品的公告,/disclosure/listedinfo/announcement/c/2015-07-30/600276_20150731_1.pdf
441,2015-08-12,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2015-08-12/600276_20150812_1.pdf
442,2015-08-25,恒瑞医药关于注射用伊立替康通过日本认证的公告,/disclosure/listedinfo/announcement/c/2015-08-25/600276_20150825_3.pdf
443,2015-08-25,恒瑞医药独立董事关于提名及聘任公司副总经理的独立意见,/disclosure/listedinfo/announcement/c/2015-08-25/600276_20150825_5.pdf
444,2015-08-25,恒瑞医药第六届董事会第十八次会议决议公告,/disclosure/listedinfo/announcement/c/2015-08-25/600276_20150825_2.pdf
445,2015-08-25,恒瑞医药半年报摘要,/disclosure/listedinfo/announcement/c/2015-08-25/600276_2015_zzy.pdf
446,2015-08-25,恒瑞医药半年报,/disclosure/listedinfo/announcement/c/2015-08-25/600276_2015_z.pdf
447,2015-09-03,恒瑞医药关于许可美国 Incyte 公司在国外开发和销售 PD-1 抗体的公告,/disclosure/listedinfo/announcement/c/2015-09-03/600276_20150903_1.pdf
448,2015-09-09,恒瑞医药关于设立创业投资合伙企业的公告,/disclosure/listedinfo/announcement/c/2015-09-09/600276_20150909_1.pdf
449,2015-09-11,恒瑞医药关于设立创业投资合伙企业的补充公告,/disclosure/listedinfo/announcement/c/2015-09-11/600276_20150911_1.pdf
450,2015-09-12,恒瑞医药关于连云港生物医药项目投资计划的公告,/disclosure/listedinfo/announcement/c/2015-09-12/600276_20150912_1.pdf
451,2015-10-01,恒瑞医药提示性公告,/disclosure/listedinfo/announcement/c/2015-10-01/600276_20151001_1.pdf
452,2015-10-01,恒瑞医药简式权益变动报告书（西藏达孜汇鑫投资管理合伙企业（有限合伙））,/disclosure/listedinfo/announcement/c/2015-10-01/600276_20151001_3.pdf
453,2015-10-01,恒瑞医药简式权益变动报告书（西藏达孜达远投资有限公司）,/disclosure/listedinfo/announcement/c/2015-10-01/600276_20151001_2.pdf
454,2015-10-28,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_4.pdf
455,2015-10-28,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_5.pdf
456,2015-10-28,恒瑞医药独立董事关于回购注销部分已授出股权激励股票的独立意见,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_8.pdf
457,2015-10-28,恒瑞医药第三季度季报,/disclosure/listedinfo/announcement/c/2015-10-28/600276_2015_3.pdf
458,2015-10-28,恒瑞医药第六届监事会第十一次会议决议公告,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_3.pdf
459,2015-10-28,恒瑞医药第六届董事会第十九次会议决议公告,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_2.pdf
460,2015-10-28,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2015-10-28/600276_20151028_6.pdf
461,2015-11-11,恒瑞医药关于吸入用七氟烷通过美国FDA认证的公告,/disclosure/listedinfo/announcement/c/2015-11-11/600276_20151111_1.pdf
462,2015-11-16,恒瑞医药关于吸入用七氟烷通过美国FDA认证的补充公告,/disclosure/listedinfo/announcement/c/2015-11-16/600276_20151116_1.pdf
463,2015-12-02,恒瑞医药关于吸入用七氟烷通过美国FDA认证的补充公告,/disclosure/listedinfo/announcement/c/2015-12-02/600276_20151202_1.pdf
464,2015-12-04,恒瑞医药关于撤回盐酸伊伐布雷定注册申请的提示性公告,/disclosure/listedinfo/announcement/c/2015-12-04/600276_20151204_1.pdf
465,2015-12-17,恒瑞医药关于收到上海证券交易所问询函的公告,/disclosure/listedinfo/announcement/c/2015-12-17/600276_20151217_1.pdf
466,2015-12-19,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2015-12-19/600276_20151219_1.pdf
467,2015-12-26,恒瑞医药关于收到上海证券交易所进一步问询函及回复的公告,/disclosure/listedinfo/announcement/c/2015-12-26/600276_20151226_1.pdf
468,2016-01-08,恒瑞医药关于撤回药品注册申请的提示性公告,/disclosure/listedinfo/announcement/c/2016-01-08/600276_20160108_1.pdf
469,2016-01-16,恒瑞医药监事会关于部分股权激励股票第一次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2016-01-16/600276_20160116_3.pdf
470,2016-01-16,恒瑞医药关于部分股权激励股票第一次解锁的公告,/disclosure/listedinfo/announcement/c/2016-01-16/600276_20160116_1.pdf
471,2016-01-16,恒瑞医药独立董事关于公司部分股权激励股票第一次解锁的独立意见,/disclosure/listedinfo/announcement/c/2016-01-16/600276_20160116_4.pdf
472,2016-01-16,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司部分股权激励股票第一次解锁的法律意见,/disclosure/listedinfo/announcement/c/2016-01-16/600276_20160116_2.pdf
473,2016-01-22,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-01-22/600276_20160122_1.pdf
474,2016-01-22,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2016-01-22/600276_20160122_2.pdf
475,2016-01-26,恒瑞医药关于撤回盐酸右氯胺酮药品注册申请的提示性公告,/disclosure/listedinfo/announcement/c/2016-01-26/600276_20160126_1.pdf
476,2016-02-20,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-02-20/600276_20160220_1.pdf
477,2016-03-09,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-03-09/600276_20160309_1.pdf
478,2016-03-10,恒瑞医药关于药品注册进度的提示性公告,/disclosure/listedinfo/announcement/c/2016-03-10/600276_20160310_1.pdf
479,2016-03-19,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-03-19/600276_20160319_1.pdf
480,2016-03-26,恒瑞医药关于获得药物临床试验批件和药品注册批件的公告,/disclosure/listedinfo/announcement/c/2016-03-26/600276_20160326_1.pdf
481,2016-04-08,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-04-08/600276_20160408_1.pdf
482,2016-04-08,恒瑞医药关于撤回磷酸瑞格列汀及片注册申请的提示性公告,/disclosure/listedinfo/announcement/c/2016-04-08/600276_20160408_2.pdf
483,2016-04-13,恒瑞医药章程修正案的公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_7.pdf
484,2016-04-13,恒瑞医药审计委员会履职情况汇总报告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_16.pdf
485,2016-04-13,恒瑞医药审计报告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_11.pdf
486,2016-04-13,恒瑞医药年报摘要,/disclosure/listedinfo/announcement/c/2016-04-13/600276_2015_nzy.pdf
487,2016-04-13,恒瑞医药年报,/disclosure/listedinfo/announcement/c/2016-04-13/600276_2015_n.pdf
488,2016-04-13,恒瑞医药内部控制审计报告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_15.pdf
489,2016-04-13,恒瑞医药关于召开2015年年度股东大会的通知,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_8.pdf
490,2016-04-13,恒瑞医药关于选举职工代表监事的公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_6.pdf
491,2016-04-13,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_4.pdf
492,2016-04-13,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_5.pdf
493,2016-04-13,恒瑞医药关于公司股票复牌的提示性公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_26.pdf
494,2016-04-13,恒瑞医药公司章程（2016修订）,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_25.pdf
495,2016-04-13,恒瑞医药独立董事提名人声明,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_22.pdf
496,2016-04-13,恒瑞医药独立董事候选人声明（薛爽）,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_20.pdf
497,2016-04-13,恒瑞医药独立董事候选人声明（王迁）,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_19.pdf
498,2016-04-13,恒瑞医药独立董事候选人声明（李援朝）,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_21.pdf
499,2016-04-13,恒瑞医药独立董事关于第六届董事会第二十二次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_10.pdf
500,2016-04-13,恒瑞医药独立董事关于第六届董事会第二十二次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_18.pdf
501,2016-04-13,恒瑞医药独立董事关于第六届董事会第二十二次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_24.pdf
502,2016-04-13,恒瑞医药第六届监事会第十二次会议决议公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_3.pdf
503,2016-04-13,恒瑞医药第六届董事会第二十二次会议决议公告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_2.pdf
504,2016-04-13,恒瑞医药：关于江苏恒瑞医药股份有限公司2015年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_12.pdf
505,2016-04-13,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_17.pdf
506,2016-04-13,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_23.pdf
507,2016-04-13,恒瑞医药2015年度内部控制评价报告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_14.pdf
508,2016-04-13,恒瑞医药2015年度独立董事述职报告,/disclosure/listedinfo/announcement/c/2016-04-13/600276_20160413_13.pdf
509,2016-04-19,恒瑞医药关于子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-04-19/600276_20160419_2.pdf
510,2016-04-19,恒瑞医药关于召开2015年度网上业绩说明会的通知,/disclosure/listedinfo/announcement/c/2016-04-19/600276_20160419_1.pdf
511,2016-04-26,恒瑞医药2016年第一季度报告,/disclosure/listedinfo/announcement/c/2016-04-26/600276_2016_1.pdf
512,2016-04-28,恒瑞医药2015年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2016-04-28/600276_20160428_1.pdf
513,2016-04-30,恒瑞医药关于子公司认购私募基金份额的公告,/disclosure/listedinfo/announcement/c/2016-04-30/600276_20160430_1.pdf
514,2016-04-30,恒瑞医药关于子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-04-30/600276_20160430_3.pdf
515,2016-04-30,恒瑞医药关于撤回药品注册申请的公告,/disclosure/listedinfo/announcement/c/2016-04-30/600276_20160430_2.pdf
516,2016-05-11,恒瑞医药关于公司董事会秘书变更的公告,/disclosure/listedinfo/announcement/c/2016-05-11/600276_20160511_4.pdf
517,2016-05-11,恒瑞医药第七届监事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2016-05-11/600276_20160511_3.pdf
518,2016-05-11,恒瑞医药第七届董事会第一次会议决议公告,/disclosure/listedinfo/announcement/c/2016-05-11/600276_20160511_2.pdf
519,2016-05-11,恒瑞医药2015年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2016-05-11/600276_20160511_1.pdf
520,2016-05-11,恒瑞医药2015年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2016-05-11/600276_20160511_5.pdf
521,2016-05-19,恒瑞医药关于撤回药品注册申请的公告,/disclosure/listedinfo/announcement/c/2016-05-19/600276_20160519_1.pdf
522,2016-05-27,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-05-27/600276_20160527_1.pdf
523,2016-06-08,恒瑞医药2015年度利润分配实施公告,/disclosure/listedinfo/announcement/c/2016-06-08/600276_20160608_1.pdf
524,2016-07-05,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-07-05/600276_20160705_1.pdf
525,2016-07-13,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_3.pdf
526,2016-07-13,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_5.pdf
527,2016-07-13,恒瑞医药关于调整限制性股票回购数量及回购价格的公告,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_4.pdf
528,2016-07-13,恒瑞医药独立董事关于第七届董事会第三次会议有关事项的独立意见,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_6.pdf
529,2016-07-13,恒瑞医药第七届监事会第二次会议决议公告,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_2.pdf
530,2016-07-13,恒瑞医药第七届董事会第三次会议决议公告,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_1.pdf
531,2016-07-13,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励相关事项的法律意见,/disclosure/listedinfo/announcement/c/2016-07-13/600276_20160713_7.pdf
532,2016-07-14,恒瑞医药监事会关于部分股权激励股票第二次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2016-07-14/600276_20160714_4.pdf
533,2016-07-14,恒瑞医药关于部分股权激励股票第二次解锁的公告,/disclosure/listedinfo/announcement/c/2016-07-14/600276_20160714_1.pdf
534,2016-07-14,恒瑞医药独立董事关于第七届董事会第三次会议有关事项的独立意见,/disclosure/listedinfo/announcement/c/2016-07-14/600276_20160714_3.pdf
535,2016-07-14,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励相关事项的法律意见,/disclosure/listedinfo/announcement/c/2016-07-14/600276_20160714_2.pdf
536,2016-08-03,恒瑞医药关于公司及控股子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2016-08-03/600276_20160803_1.pdf
537,2016-08-20,恒瑞医药关于子公司获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-08-20/600276_20160820_1.pdf
538,2016-08-24,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-08-24/600276_20160824_1.pdf
539,2016-08-30,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_4.pdf
540,2016-08-30,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_5.pdf
541,2016-08-30,恒瑞医药独立董事关于回购注销部分已授出股权激励股票的独立意见,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_7.pdf
542,2016-08-30,恒瑞医药第七届监事会第三次会议决议公告,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_3.pdf
543,2016-08-30,恒瑞医药第七届董事会第四次会议决议公告,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_2.pdf
544,2016-08-30,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2016-08-30/600276_20160830_8.pdf
545,2016-08-30,恒瑞医药2016年半年度报告摘要,/disclosure/listedinfo/announcement/c/2016-08-30/600276_2016_zzy.pdf
546,2016-08-30,恒瑞医药2016年半年度报告,/disclosure/listedinfo/announcement/c/2016-08-30/600276_2016_z.pdf
547,2016-09-09,恒瑞医药关于子公司获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-09-09/600276_20160909_1.pdf
548,2016-09-15,恒瑞医药关于回购股份的进展公告,/disclosure/listedinfo/announcement/c/2016-09-15/600276_20160915_1.pdf
549,2016-09-20,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-09-20/600276_20160920_1.pdf
550,2016-10-15,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-10-15/600276_20161015_1.pdf
551,2016-10-20,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-10-20/600276_20161020_2.pdf
552,2016-10-20,恒瑞医药关于获得新药证书和药品注册批件的公告,/disclosure/listedinfo/announcement/c/2016-10-20/600276_20161020_1.pdf
553,2016-10-27,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-10-27/600276_20161027_1.pdf
554,2016-10-29,恒瑞医药关于授权利用闲置自有资金投资低风险理财产品的公告,/disclosure/listedinfo/announcement/c/2016-10-29/600276_20161029_3.pdf
555,2016-10-29,恒瑞医药独立董事关于授权利用闲置自有资金投资低风险理财产品的独立意见,/disclosure/listedinfo/announcement/c/2016-10-29/600276_20161029_5.pdf
556,2016-10-29,恒瑞医药第七届董事会第五次会议决议公告,/disclosure/listedinfo/announcement/c/2016-10-29/600276_20161029_2.pdf
557,2016-10-29,恒瑞医药2016年第三季度报告,/disclosure/listedinfo/announcement/c/2016-10-29/600276_2016_3.pdf
558,2016-11-04,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-11-04/600276_20161104_1.pdf
559,2016-11-11,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-11-11/600276_20161111_1.pdf
560,2016-11-16,恒瑞医药关于公司及控股子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2016-11-16/600276_20161116_1.pdf
561,2016-11-17,恒瑞医药关于公司及控股子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2016-11-17/600276_20161117_1.pdf
562,2016-11-19,恒瑞医药关于子公司获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-11-19/600276_20161119_1.pdf
563,2016-12-01,恒瑞医药关于签署许可协议的公告,/disclosure/listedinfo/announcement/c/2016-12-01/600276_20161201_1.pdf
564,2016-12-03,恒瑞医药关于签署许可协议的补充公告,/disclosure/listedinfo/announcement/c/2016-12-03/600276_20161203_1.pdf
565,2016-12-07,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2016-12-07/600276_20161207_2.pdf
566,2016-12-07,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2016-12-07/600276_20161207_1.pdf
567,2016-12-28,恒瑞医药关于获得审批意见通知件的公告,/disclosure/listedinfo/announcement/c/2016-12-28/600276_20161228_1.pdf
568,2017-01-05,恒瑞医药监事会关于部分股权激励股票第二次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2017-01-05/600276_20170105_4.pdf
569,2017-01-05,恒瑞医药独立董事关于公司部分股权激励股票第二次解锁的独立意见,/disclosure/listedinfo/announcement/c/2017-01-05/600276_20170105_3.pdf
570,2017-01-05,恒瑞医药第七届董事会第六次会议决议公告,/disclosure/listedinfo/announcement/c/2017-01-05/600276_20170105_1.pdf
571,2017-01-05,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励解锁事项的法律意见,/disclosure/listedinfo/announcement/c/2017-01-05/600276_20170105_2.pdf
572,2017-01-07,恒瑞医药关于股东权益变动的提示性公告,/disclosure/listedinfo/announcement/c/2017-01-07/600276_20170107_1.pdf
573,2017-01-10,恒瑞医药监事会关于部分股权激励股票第二次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2017-01-10/600276_20170110_4.pdf
574,2017-01-10,恒瑞医药关于部分股权激励股票第二次解锁的公告,/disclosure/listedinfo/announcement/c/2017-01-10/600276_20170110_1.pdf
575,2017-01-10,恒瑞医药独立董事关于公司部分股权激励股票第二次解锁的独立意见,/disclosure/listedinfo/announcement/c/2017-01-10/600276_20170110_3.pdf
576,2017-01-10,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励解锁事项的法律意见,/disclosure/listedinfo/announcement/c/2017-01-10/600276_20170110_2.pdf
577,2017-01-17,恒瑞医药关于获得药物临床试验通知的公告,/disclosure/listedinfo/announcement/c/2017-01-17/600276_20170117_2.pdf
578,2017-01-17,恒瑞医药关于公司及控股子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-01-17/600276_20170117_1.pdf
579,2017-01-25,恒瑞医药关于获得药物临床试验通知的公告,/disclosure/listedinfo/announcement/c/2017-01-25/600276_20170125_1.pdf
580,2017-02-08,恒瑞医药关于获得美国FDA批准文号的公告,/disclosure/listedinfo/announcement/c/2017-02-08/600276_20170208_1.pdf
581,2017-02-09,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-02-09/600276_20170209_1.pdf
582,2017-02-09,恒瑞医药关于获得新药证书和药品注册批件的公告,/disclosure/listedinfo/announcement/c/2017-02-09/600276_20170209_2.pdf
583,2017-02-21,恒瑞医药关于子公司获得药品GMP证书的公告,/disclosure/listedinfo/announcement/c/2017-02-21/600276_20170221_2.pdf
584,2017-02-21,恒瑞医药关于获得美国FDA批准文号的公告,/disclosure/listedinfo/announcement/c/2017-02-21/600276_20170221_1.pdf
585,2017-02-27,恒瑞医药关于公司主要产品新进入国家医保目录的公告,/disclosure/listedinfo/announcement/c/2017-02-27/600276_20170227_5.pdf
586,2017-02-27,恒瑞医药关于公司董事辞职的公告,/disclosure/listedinfo/announcement/c/2017-02-27/600276_20170227_6.pdf
587,2017-03-09,恒瑞医药关于公司及子公司获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-03-09/600276_20170309_1.pdf
588,2017-03-09,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2017-03-09/600276_20170309_3.pdf
589,2017-03-11,恒瑞医药章程修正案,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_4.pdf
590,2017-03-11,恒瑞医药审计委员会履职情况汇总报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_14.pdf
591,2017-03-11,恒瑞医药关于召开2016年年度股东大会的通知,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_3.pdf
592,2017-03-11,恒瑞医药关于调整利用闲置自有资金购买理财产品授权额度及所购买理财产品的发行主体范围的公告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_17.pdf
593,2017-03-11,恒瑞医药公司章程（2017年修订）,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_15.pdf
594,2017-03-11,恒瑞医药独立董事关于第七届董事会第七次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_8.pdf
595,2017-03-11,恒瑞医药第七届监事会第五次会议决议公告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_5.pdf
596,2017-03-11,恒瑞医药第七届董事会第七次会议决议公告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_6.pdf
597,2017-03-11,恒瑞医药：内部控制审计报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_13.pdf
598,2017-03-11,恒瑞医药：关于江苏恒瑞医药股份有限公司2016年度非经营性资金占用及其他关联资金往来情况的专项说明,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_10.pdf
599,2017-03-11,恒瑞医药：2016年度审计报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_9.pdf
600,2017-03-11,恒瑞医药2016年年度报告摘要,/disclosure/listedinfo/announcement/c/2017-03-11/600276_2016_nzy.pdf
601,2017-03-11,恒瑞医药2016年年度报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_2016_n.pdf
602,2017-03-11,恒瑞医药2016年度内部控制评价报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_19.pdf
603,2017-03-11,恒瑞医药2016年度独立董事述职报告,/disclosure/listedinfo/announcement/c/2017-03-11/600276_20170311_11.pdf
604,2017-03-16,恒瑞医药关于获得药物上市许可的公告,/disclosure/listedinfo/announcement/c/2017-03-16/600276_20170316_1.pdf
605,2017-03-23,恒瑞医药关于召开2016年度网上业绩说明会的通知,/disclosure/listedinfo/announcement/c/2017-03-23/600276_20170323_2.pdf
606,2017-03-23,恒瑞医药2016年年度股东大会会议资料,/disclosure/listedinfo/announcement/c/2017-03-23/600276_20170323_1.pdf
607,2017-03-29,恒瑞医药关于获得药品GMP证书的公告,/disclosure/listedinfo/announcement/c/2017-03-29/600276_20170329_1.pdf
608,2017-04-01,恒瑞医药关于股东权益变动的进展公告,/disclosure/listedinfo/announcement/c/2017-04-01/600276_20170401_1.pdf
609,2017-04-07,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-04-07/600276_20170407_1.pdf
610,2017-04-10,恒瑞医药2016年年度股东大会决议公告,/disclosure/listedinfo/announcement/c/2017-04-10/600276_20170410_1.pdf
611,2017-04-10,恒瑞医药2016年年度股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2017-04-10/600276_20170410_2.pdf
612,2017-04-14,恒瑞医药关于在江苏投资设立子公司的公告,/disclosure/listedinfo/announcement/c/2017-04-14/600276_20170414_2.pdf
613,2017-04-14,恒瑞医药第七届董事会第八次会议决议公告,/disclosure/listedinfo/announcement/c/2017-04-14/600276_20170414_1.pdf
614,2017-04-19,恒瑞医药关于获得药物临床试验通知的公告,/disclosure/listedinfo/announcement/c/2017-04-19/600276_20170419_1.pdf
615,2017-04-21,恒瑞医药2017年第一季度报告,/disclosure/listedinfo/announcement/c/2017-04-21/600276_2017_1.pdf
616,2017-05-04,恒瑞医药关于获得药物临床试验通知的公告,/disclosure/listedinfo/announcement/c/2017-05-04/600276_20170504_1.pdf
617,2017-05-05,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2017-05-05/600276_20170505_1.pdf
618,2017-05-05,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2017-05-05/600276_20170505_4.pdf
619,2017-05-05,恒瑞医药独立董事关于回购注销部分已授出股权激励股票的独立意见,/disclosure/listedinfo/announcement/c/2017-05-05/600276_20170505_2.pdf
620,2017-05-05,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司回购注销部分限制性股票的法律意见,/disclosure/listedinfo/announcement/c/2017-05-05/600276_20170505_3.pdf
621,2017-05-22,恒瑞医药2016年年度权益分派实施公告,/disclosure/listedinfo/announcement/c/2017-05-22/600276_20170522_1.pdf
622,2017-05-24,恒瑞医药关于开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2017-05-24/600276_20170524_2.pdf
623,2017-05-24,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-05-24/600276_20170524_1.pdf
624,2017-06-10,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_6.pdf
625,2017-06-10,恒瑞医药关于调整限制性股票回购数量及回购价格的公告,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_3.pdf
626,2017-06-10,恒瑞医药独立董事关于第七届董事会第十一次会议有关事项的独立意见,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_4.pdf
627,2017-06-10,恒瑞医药第七届监事会第八次会议决议公告,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_2.pdf
628,2017-06-10,恒瑞医药第七届董事会第十一次会议决议公告,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_1.pdf
629,2017-06-10,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励调整事项的法律意见,/disclosure/listedinfo/announcement/c/2017-06-10/600276_20170610_5.pdf
630,2017-06-27,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-06-27/600276_20170627_1.pdf
631,2017-06-27,恒瑞医药关于公司及控股子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2017-06-27/600276_20170627_2.pdf
632,2017-06-29,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2017-06-29/600276_20170629_1.pdf
633,2017-07-12,恒瑞医药关于回购注销部分已授出股权激励股票的公告,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_5.pdf
634,2017-07-12,恒瑞医药关于回购注销部分限制性股票通知债权人的公告,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_6.pdf
635,2017-07-12,恒瑞医药独立董事关于第七届董事会第十二次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_2.pdf
636,2017-07-12,恒瑞医药第七届监事会第九次会议决议公告,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_4.pdf
637,2017-07-12,恒瑞医药第七届董事会第十二次会议决议公告,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_1.pdf
638,2017-07-12,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励相关事项的法律意见,/disclosure/listedinfo/announcement/c/2017-07-12/600276_20170712_3.pdf
639,2017-07-15,恒瑞医药关于获得药物上市许可的公告,/disclosure/listedinfo/announcement/c/2017-07-15/600276_20170715_3.pdf
640,2017-07-15,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-07-15/600276_20170715_2.pdf
641,2017-07-20,恒瑞医药关于部分股权激励股票第三次解锁的公告,/disclosure/listedinfo/announcement/c/2017-07-20/600276_20170720_1.pdf
642,2017-07-21,恒瑞医药关于公司主要产品新进入国家医保目录的公告,/disclosure/listedinfo/announcement/c/2017-07-21/600276_20170721_1.pdf
643,2017-07-25,恒瑞医药关于公司主要产品新进入国家医保目录的补充公告,/disclosure/listedinfo/announcement/c/2017-07-25/600276_20170725_1.pdf
644,2017-07-28,恒瑞医药关于开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2017-07-28/600276_20170728_1.pdf
645,2017-08-05,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-08-05/600276_20170805_1.pdf
646,2017-08-05,恒瑞医药关于公司及子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2017-08-05/600276_20170805_2.pdf
647,2017-08-15,恒瑞医药关于获得美国FDA批准文号的公告,/disclosure/listedinfo/announcement/c/2017-08-15/600276_20170815_2.pdf
648,2017-08-15,恒瑞医药关于公司及子公司开展药物临床试验的公告,/disclosure/listedinfo/announcement/c/2017-08-15/600276_20170815_1.pdf
649,2017-08-30,恒瑞医药2017年半年度报告摘要,/disclosure/listedinfo/announcement/c/2017-08-30/600276_2017_zzy.pdf
650,2017-08-30,恒瑞医药2017年半年度报告,/disclosure/listedinfo/announcement/c/2017-08-30/600276_2017_z.pdf
651,2017-09-05,恒瑞医药关于获得美国FDA批准文号的公告,/disclosure/listedinfo/announcement/c/2017-09-05/600276_20170905_1.pdf
652,2017-09-12,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2017-09-12/600276_20170912_1.pdf
653,2017-09-22,恒瑞医药关于注销已回购部分股权激励股票的公告,/disclosure/listedinfo/announcement/c/2017-09-22/600276_20170922_1.pdf
654,2017-09-27,恒瑞医药澄清公告,/disclosure/listedinfo/announcement/c/2017-09-27/600276_20170927_1.pdf
655,2017-10-09,恒瑞医药关于公司产品注册申请进展的说明公告,/disclosure/listedinfo/announcement/c/2017-10-09/600276_20171009_1.pdf
656,2017-10-19,恒瑞医药2017年第三季度报告,/disclosure/listedinfo/announcement/c/2017-10-19/600276_2017_3.pdf
657,2017-11-01,恒瑞医药限制性股票激励计划激励对象名单,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_7.pdf
658,2017-11-01,恒瑞医药关于召开2017年第一次临时股东大会的通知,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_9.pdf
659,2017-11-01,恒瑞医药关于公司董事辞职的公告,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_12.pdf
660,2017-11-01,恒瑞医药关于独立董事公开征集投票权的公告,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_10.pdf
661,2017-11-01,恒瑞医药独立董事关于2017年度限制性股票激励计划（草案）及相关事项的独立意见,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_3.pdf
662,2017-11-01,恒瑞医药第七届监事会第十二次会议决议公告,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_11.pdf
663,2017-11-01,恒瑞医药第七届监事会第十二次会议决议,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_5.pdf
664,2017-11-01,恒瑞医药第七届董事会第十五次会议决议公告,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_1.pdf
665,2017-11-01,恒瑞医药：北京市中伦律师事务所关于《江苏恒瑞医药股份有限公司2017年度限制性股票激励计划（草案）》的法律意见,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_4.pdf
666,2017-11-01,恒瑞医药2017年度限制性股票激励计划实施考核管理办法,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_6.pdf
667,2017-11-01,恒瑞医药2017年度限制性股票激励计划（草案）摘要,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_2.pdf
668,2017-11-01,恒瑞医药2017年度限制性股票激励计划（草案）,/disclosure/listedinfo/announcement/c/2017-11-01/600276_20171101_8.pdf
669,2017-11-04,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-11-04/600276_20171104_1.pdf
670,2017-11-07,恒瑞医药关于获得药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-11-07/600276_20171107_1.pdf
671,2017-11-10,恒瑞医药关于2017年第一次临时股东大会增加临时提案的公告,/disclosure/listedinfo/announcement/c/2017-11-10/600276_20171110_3.pdf
672,2017-11-10,恒瑞医药独立董事关于第七届董事会第十六次会议有关事项的意见,/disclosure/listedinfo/announcement/c/2017-11-10/600276_20171110_2.pdf
673,2017-11-10,恒瑞医药第七届董事会第十六次会议决议公告,/disclosure/listedinfo/announcement/c/2017-11-10/600276_20171110_1.pdf
674,2017-11-16,恒瑞医药2017年第一次临时股东大会会议资料,/disclosure/listedinfo/announcement/c/2017-11-16/600276_20171116_1.pdf
675,2017-11-18,恒瑞医药监事会关于2017年度限制性股票激励计划激励对象人员名单的审核意见及公示情况说明,/disclosure/listedinfo/announcement/c/2017-11-18/600276_20171118_1.pdf
676,2017-11-24,恒瑞医药关于2017年度限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告,/disclosure/listedinfo/announcement/c/2017-11-24/600276_20171124_3.pdf
677,2017-11-24,恒瑞医药2017年第一次临时股东大会决议公告,/disclosure/listedinfo/announcement/c/2017-11-24/600276_20171124_1.pdf
678,2017-11-24,恒瑞医药2017年第一次临时股东大会的法律意见书,/disclosure/listedinfo/announcement/c/2017-11-24/600276_20171124_2.pdf
679,2017-11-25,恒瑞医药限制性股票激励计划激励对象名单,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_6.pdf
680,2017-11-25,恒瑞医药关于向公司2017年度限制性股票激励计划激励对象首次授予限制性股票的公告,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_3.pdf
681,2017-11-25,恒瑞医药独立董事关于第七届董事会第十七次会议相关事项的独立意见,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_4.pdf
682,2017-11-25,恒瑞医药第七届监事会第十三次会议决议公告,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_2.pdf
683,2017-11-25,恒瑞医药第七届董事会第十七次会议决议公告,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_1.pdf
684,2017-11-25,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司2017年度限制性股票激励计划首次授予的法律意见,/disclosure/listedinfo/announcement/c/2017-11-25/600276_20171125_5.pdf
685,2017-11-29,恒瑞医药关于获得美国FDA批准文号的公告,/disclosure/listedinfo/announcement/c/2017-11-29/600276_20171129_1.pdf
686,2017-12-06,恒瑞医药关于获得美国FDA国际多中心临床试验资格的公告,/disclosure/listedinfo/announcement/c/2017-12-06/600276_20171206_1.pdf
687,2017-12-11,恒瑞医药关于公司产品完成II期临床试验的提示性公告,/disclosure/listedinfo/announcement/c/2017-12-11/600276_20171211_1.pdf
688,2017-12-14,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2017-12-14/600276_20171214_1.pdf
689,2017-12-30,恒瑞医药关于公司高管辞职的公告,/disclosure/listedinfo/announcement/c/2017-12-30/600276_20171230_1.pdf
690,2018-01-05,恒瑞医药关于许可美国Arcutis公司在国外开发和销售JAK1抑制剂的公告,/disclosure/listedinfo/announcement/c/2018-01-05/600276_20180105_1.pdf
691,2018-01-08,恒瑞医药关于签署许可协议的补充公告,/disclosure/listedinfo/announcement/c/2018-01-08/600276_20180108_1.pdf
692,2018-01-10,恒瑞医药关于与美国TG公司签订许可协议的公告,/disclosure/listedinfo/announcement/c/2018-01-10/600276_20180110_2.pdf
693,2018-01-10,恒瑞医药关于签署许可协议的补充公告,/disclosure/listedinfo/announcement/c/2018-01-10/600276_20180110_1.pdf
694,2018-01-11,恒瑞医药监事会关于部分股权激励股票第三次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2018-01-11/600276_20180111_3.pdf
695,2018-01-11,恒瑞医药独立董事关于公司部分股权激励股票第三次解锁的独立意见,/disclosure/listedinfo/announcement/c/2018-01-11/600276_20180111_4.pdf
696,2018-01-11,恒瑞医药第七届董事会第十八次会议决议公告,/disclosure/listedinfo/announcement/c/2018-01-11/600276_20180111_1.pdf
697,2018-01-11,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励相关事项的法律意见,/disclosure/listedinfo/announcement/c/2018-01-11/600276_20180111_2.pdf
698,2018-01-17,恒瑞医药关于获得审批意见通知件和药物临床试验批件的公告,/disclosure/listedinfo/announcement/c/2018-01-17/600276_20180117_1.pdf
699,2018-01-17,恒瑞医药关于获得美国FDA药品临床试验资格的公告,/disclosure/listedinfo/announcement/c/2018-01-17/600276_20180117_2.pdf
700,2018-01-20,恒瑞医药关于2017年度限制性股票激励计划首次授予结果的公告,/disclosure/listedinfo/announcement/c/2018-01-20/600276_20180120_1.pdf
701,2018-01-23,恒瑞医药：验资报告,/disclosure/listedinfo/announcement/c/2018-01-23/600276_20180123_1.pdf
702,2018-01-26,恒瑞医药监事会关于部分股权激励股票第三次解锁的书面审核意见,/disclosure/listedinfo/announcement/c/2018-01-26/600276_20180126_4.pdf
703,2018-01-26,恒瑞医药关于部分股权激励股票第三次解锁的公告,/disclosure/listedinfo/announcement/c/2018-01-26/600276_20180126_1.pdf
704,2018-01-26,恒瑞医药独立董事关于公司部分股权激励股票第三次解锁的独立意见,/disclosure/listedinfo/announcement/c/2018-01-26/600276_20180126_3.pdf
705,2018-01-26,恒瑞医药：北京市中伦律师事务所关于江苏恒瑞医药股份有限公司股权激励相关事项的法律意见,/disclosure/listedinfo/announcement/c/2018-01-26/600276_20180126_2.pdf
706,2018-01-31,恒瑞医药关于公司产品拟纳入优先审评程序的公告,/disclosure/listedinfo/announcement/c/2018-01-31/600276_20180131_1.pdf
707,2018-02-15,恒瑞医药关于许可美国 Incyte 公司在国外开发和销售PD-1抗体项目进展的提示性公告,/disclosure/listedinfo/announcement/c/2018-02-15/600276_20180215_1.pdf
